How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,564 results for

NIH Stroke Scale

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

121. Training Guidelines for Intra-arterial Catheter Directed Treatment of Acute Ischemic Stroke

series of cases to date reported an inci- dence of permanent neurologic deficit or death of less than 0.2% (74–76). Pa- tients with symptomatic atherosclerotic cerebrovascular disease (ie, ipsilateral transient ischemic attack or stroke) haveatwotothreetimesgreaterrisk of stroke from diagnostic cerebral angiography (0.5%–5.7% risk of per- manent deficit) compared with asymptomatic patients (0.1%–1.2% risk) (57–61,66–70,73). Operator ex- perience, as measured by decreased complications and decreased (...) intheinterventionalcareofpatientswith acuteischemicstroke.Thistrainingmust, at a minimum, include neuroanatomy, cerebrovascular hemodynamics, stroke syndromes,strokemimics,collateralce- rebrovascular pathways, clinical neuro- logic examination (including the Na- tional Institutes of Health Stroke Scale), clinical neurologic findings related to specific vascular ischemic insults, and neuroimaging of acute stroke by tech- niques such as CT, MRI, CT angiogra- phy, MR angiography, cerebral angiog- raphy, and CT/MR and nuclear cerebral

2013 Society of Interventional Radiology

122. CVA Management

, CEREBROVASCULAR ACCIDENT , Strokes , CEREBRAL INFARCTION , Stroke , Cerebrovascular Accident , CVA (cerebral vascular accident) , cerebral vascular accident , Stroke/CVA unspecified , Accident cerebrovascular , Cerebrovascular accident NOS , Brain Vascular Accident , Brain Vascular Accidents , Vascular Accident, Brain , Vascular Accidents, Brain , CVA (Cerebrovascular Accident) , Apoplexy, Cerebrovascular , Cerebrovascular Apoplexy , Cerebral Stroke , Cerebral Strokes , Stroke, Cerebral , Strokes, Cerebral (...) , Cerebrovascular Stroke , Cerebrovascular Strokes , Stroke, Cerebrovascular , Strokes, Cerebrovascular , Stroke NOS , Stroke [Disease/Finding] , cerebrovascular accidents , stroke cerebral , stroke , strokes , vascular cerebral accident , vascular brain accident , cerebral stroke , cerebrovascular stroke , CVAs (Cerebrovascular Accident) , Brain Attack , Brain attack , Cerebrovascular accidents , Stroke and cerebrovascular accident unspecified (disorder) , Stroke/CVA - undefined , Accident - cerebrovascular

2018 FP Notebook

123. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation

and the prevention of stroke in patients with stroke or transient ischemic attack (TIA), 5 we review recent trials testing the safety and effi- cacy of a thrombin inhibitor (dabigatran) and 2 factor Xa inhibitors (rivaroxaban and apixaban) in preventing stroke in patients with AF, and we revise management recom- mendations. 4,5 Recommendations follow the AHA’s and the American College of Cardiology’s methods of classifying the level of certainty of the treatment effect and the class of evidence (Table 1 (...) with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:227–276. 6. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, Petersen P. Selecting patients with atrial fibrillation for anticoagu- lation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110:2287–2292. 7. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical

2012 American Academy of Neurology

124. Inclusion of stroke in cardiovascular risk prediction instruments

Carotid Artery Disease Symptomatic carotid artery disease is symptomatic by virtue of leading to stroke or transient ischemic attack (TIA), includingretinalevents.Thus,symptomaticcarotiddiseaseis the one variety of cerebrovascular disease that is already explicitly included among risk equivalents. As noted previ- ously, however, symptomatic carotid disease only accounts for10% of cerebral infarctions. Seven studies are cited to support carotid disease as a risk equivalent, with sample sizes ranging (...) 1998 Downloaded from http://ahajournals.org by on March 27, 2019before consideration and approval by the AHA Science Advisory and Coordinating Committee. There are several reasons to consider stroke patients, and particularly patients with atherosclerotic stroke, among the groups of patients at high absolute risk of coronary and cardiovascular disease. First, evidence suggests that patients with ischemic stroke are at high absolute risk of fatal or nonfatal myocardial infarction or sudden death

2012 American Academy of Neurology

125. Comparative Effectiveness of Pre-stroke Aspirin on Stroke Severity and Outcome. Full Text available with Trip Pro

Comparative Effectiveness of Pre-stroke Aspirin on Stroke Severity and Outcome. The effect of prestroke aspirin use on initial severity, hemorrhagic transformation, and functional outcome of ischemic stroke is uncertain.Using a multicenter stroke registry database, patients with acute ischemic stroke of three subtypes (large artery atherosclerosis [LAA], small vessel occlusion [SVO], or cardioembolism [CE]) were identified. NIH stroke scale (NIHSS) and hemorrhagic transformation at presentation (...) and discharge modified Rankin Scale (mRS) were compared between prestroke aspirin users and nonusers.Among the 10,433 patients, 1,914 (18.3%) reported prestroke aspirin use. On crude analysis, initial NIHSS scores of aspirin users were higher than nonusers (mean difference: 0.35; 95% confidence interval [CI]: 0.04-0.66). However, a multivariable analysis with an application of inverse probability of treatment weighting based on a propensity score of prestroke aspirin, having an interaction effect

2016 Annals of Neurology

126. Stroke Motor Rehabilitation and Recovery Study

provided by Leigh R. Hochberg, MD, PhD., Massachusetts General Hospital: Rehabilitation Neurorehabilitation Neurotechnology Neurorecovery Neurorestoration Additional relevant MeSH terms: Layout table for MeSH terms Stroke Ischemia Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Pathologic Processes (...) Completion Date : June 30, 2022 Estimated Study Completion Date : June 30, 2023 Resource links provided by the National Library of Medicine related topics: Groups and Cohorts Go to Outcome Measures Go to Primary Outcome Measures : Change in National Institute of Health Stroke Scale [ Time Frame: Time 1: Within 10 days of ischemic stroke date; Time 2: 42 days after stroke date (+/- 10 days); Time 3: 84 days after stroke date (+/- 10 days); Time 4: 168 days after stroke date (+/- 10 days); Time 5: 365 days

2017 Clinical Trials

127. Neuroprotection in Acute Ischemic Stroke

: neuroprotection antioxidant Additional relevant MeSH terms: Layout table for MeSH terms Stroke Ischemia Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Cardiovascular Diseases Pathologic Processes Minocycline Anti-Bacterial Agents Anti-Infective Agents (...) Hydrogen Other: Placebo Minocycline Phase 2 Phase 3 Detailed Description: This will be a pilot trial exploring the ability of a novel combination ("H2M") of molecular hydrogen (an antioxidant) and minocycline (a widely used antibiotic known to inhibit the activation of matrix metallo-proteinase-9 and poly(ADP-ribose) polymerase), to protect brain tissue from ischemia/reperfusion injury that occurs during and after an ischemic stroke. Both hydrogen and minocycline have excellent safety profiles, have

2017 Clinical Trials

128. Effect of informed consent on patient characteristics in a stroke thrombolysis trial. Full Text available with Trip Pro

patients with unknown time of symptom onset running in 6 European countries. Patients providing informed consent by themselves were compared with patients enrolled by proxy consent. Baseline clinical measures were compared between groups.In 359 (35.7%) patients, informed consent was by proxy. Patients with proxy consent were older (median 71 vs 66 years, p < 0.0001) and had a higher frequency of arterial hypertension (58.2% vs 43.4%, p < 0.0001). They showed higher scores on the NIH Stroke Scale (...) Effect of informed consent on patient characteristics in a stroke thrombolysis trial. To determine whether the manner of consent, i.e., informed consent by patients themselves or informed consent by proxy, affects clinical characteristics of samples of acute stroke patients enrolled in clinical trials.We analyzed the manner of obtaining informed consent in the first 1,005 patients from WAKE-UP, an investigator-initiated, randomized, placebo-controlled trial of MRI-based thrombolysis in stroke

2017 Neurology Controlled trial quality: predicted high

129. Intake of potassium- and magnesium-enriched salt improves functional outcome after stroke: a randomized, multicenter, double-blind controlled trial. Full Text available with Trip Pro

: This was a double-blind, randomized controlled trial comprising 291 discharged stroke patients with modified Rankin scale (mRS) ≤4. There were 3 arms: 1) regular salt (Na salt) (n = 99), 2) potassium-enriched salt (K salt) (n = 97), and 3) potassium- and magnesium-enriched salt (K/Mg salt) (n = 95). The NIH Stroke Scale (NIHSS), Barthel Index (BI), and mRS were evaluated at discharge, at 3 mo, and at 6 mo. A good neurologic performance was defined by NIHSS = 0, BI = 100, and mRS ≤1.Results: After the 6-mo (...) Intake of potassium- and magnesium-enriched salt improves functional outcome after stroke: a randomized, multicenter, double-blind controlled trial. Background: Stroke is one of the leading causes of mortality and neurologic deficits. Management measures to improve neurologic outcomes are in great need. Our previous intervention trial in elderly subjects successfully used salt as a carrier for potassium, demonstrating a 41% reduction in cardiovascular mortality by switching to potassium

2017 American Journal of Clinical Nutrition Controlled trial quality: predicted high

130. Biological age is better than chronological as predictor of 3-month outcome in ischemic stroke. (Abstract)

), vascular risk factors, initial stroke severity, recanalization treatment, and previous and 3-month modified Rankin Scale (p-mRS and 3-mRS, respectively) were registered. B-age was estimated with an algorithm, based on DNA methylation in 71 CpGs. Bivariate analysis determined variables associated with 3-mRS for inclusion in ordinal multivariate analysis.After ordinal regressions for 3-month ischemic stroke outcome (3-mRS), b-age was associated with outcome (odds ratio 1.04 [95% confidence interval 1.01 (...) -1.07]), nullifying c-age. Stepwise regression kept b-age, basal NIH Stroke Scale, sex, p-mRS, and recanalization treatment as better explanatory variables, instead of c-age. These results were successfully replicated in an independent cohort.B-age, estimated by DNA methylation, is an independent predictor of ischemic stroke outcome regardless of chronological years.© 2017 American Academy of Neurology.

2017 Neurology

131. Outcome after stroke thrombolysis in patients &gt;80 years treated within 3 hours vs &gt;3-4.5 hours. Full Text available with Trip Pro

in >3-4.5 hours). Of these, 8,658 (2,157 in >3-4.5 hours) were treated otherwise according to the European Summary of Product Characteristics (EU SmPC) criteria for alteplase. Outcomes were 3-month functional independence (modified Rankin Scale score 0-2), mortality, and symptomatic intracerebral hemorrhage (SICH)/SITS. Results were compared between the groups treated in >3 to 4.5 and ≤3 hours.Median age was 84 years; 61% were female in both groups. Median NIH Stroke Scale score was 12 vs 14 (...) Outcome after stroke thrombolysis in patients >80 years treated within 3 hours vs >3-4.5 hours. To determine outcomes and risks of IV thrombolysis (IVT) in patients with acute ischemic stroke (AIS) >80 years of age within 3 hours compared to >3 to 4.5 hours recorded in the Safe Implementation of Treatment in Stroke (SITS) International Stroke Thrombolysis Registry.A total of 14,240 (year 2003-2015) patients >80 years of age with AIS were treated with IVT ≤4.5 hours of stroke onset (3,558

2017 Neurology

132. Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke. Full Text available with Trip Pro

Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke. To examine the association between serum matrix metalloproteinases-9 (MMP-9) levels and prognosis of acute ischemic stroke.We measured serum MMP-9 levels in 3,186 participants (2,008 men and 1,178 women) from the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS). Study outcome data on death, major disability (modified Rankin Scale score ≥3), and vascular disease were collected at 3 months after stroke (...) onset.During 3 months of follow-up, 767 participants (24.6%) experienced major disability or died. Serum MMP-9 was significantly associated with an increased risk of death and major disability after adjustment for age, sex, time from onset to randomization, current smoking, alcohol drinking, admission NIH Stroke Scale score, diastolic blood pressure, plasma glucose, white blood cell counts, use of antihypertensive medications, and history of hypertension, coronary heart disease, and diabetes mellitus

2017 Neurology Controlled trial quality: uncertain

133. Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke

and Medstar Washington Hospital Center) who had a stroke evaluation by the NIH stroke team will be eligible for enrollment. Enrolled subjects who meet the inclusion/exclusion criteria will be followed serially with MRI. The first research evaluation will be within 3-4 months of the qualifying event whenever possible, but could be up to 6 months. Research procedures will consist of an MRI, interval history and cognitive/clinical scaling. Research procedures will occur every 3 months for the first year (...) allergic reaction, renal insufficiency) Known diagnosis that is thought to be the cause of their WMH (e.g. multiple sclerosis) other than chronic cerebrovascular disease, cerebral autosomal dominant arteriopathy with subcortical infarcts (CADASIL), or migraine. Clinically significant medical or neurological disorders that might expose the patient to undue risk of harm, confound study outcomes or prevent the participant from completing the study; examples of such conditions include but are not limited

2017 Clinical Trials

134. Frequency, determinants, and effects of early seizures after thrombolysis for acute ischemic stroke: The ENCHANTED trial Full Text available with Trip Pro

days.Data were available for 3,139 acute ischemic stroke participants, of whom 42 (1.3%) had seizures at a median 22.7 hours after the onset of symptoms. Baseline variables associated with seizures were male sex (odds ratio [OR] 2.19, 95% confidence interval [CI] 1.07-4.50), severe neurologic impairment (NIH Stroke Scale score ≥10; OR 2.16, 95% CI 1.06-4.40), and fever (OR 4.55, 95% CI 2.37-8.71). Seizures independently predicted poor recovery: death or major disability (OR 2.88, 95% CI 1.28-6.47 (...) Frequency, determinants, and effects of early seizures after thrombolysis for acute ischemic stroke: The ENCHANTED trial Seizures after ischemic stroke have not been well-studied. We aim to determine the frequency, determinants, and significance of early seizures after thrombolysis for acute ischemic stroke.Data are from the Enhanced Control of Hypertension and Thrombolysis Stroke Study (ENCHANTED), an international, multicenter, randomized controlled trial where patients with acute ischemic

2017 Neurology: Clinical Practice Controlled trial quality: predicted high

135. TREVO stent-retriever mechanical thrombectomy for acute ischemic stroke secondary to large vessel occlusion registry Full Text available with Trip Pro

device in everyday clinical practice.Twenty-three centers enrolled consecutive AIS patients treated from March 2013 through August 2015 with the Trevo device. The primary outcome was defined as achieving a Thrombolysis in Cerebral Infarction (TICI) score of ≥2b. Secondary outcomes included 90-day modified Rankin Scale (mRS), mortality, and symptomatic intracranial hemorrhage (sICH).A total of 634patients were included. Mean age was 66.1±14.8 years and mean baseline NIH Stroke Scale (NIHSS) score (...) TREVO stent-retriever mechanical thrombectomy for acute ischemic stroke secondary to large vessel occlusion registry Recent randomized clinical trials (RCTs) demonstrated the efficacy of mechanical thrombectomy using stent-retrievers in patients with acute ischemic stroke (AIS) with large vessel occlusions; however, it remains unclear if these results translate to a real-world setting. The TREVO Stent-Retriever Acute Stroke (TRACK) multicenter Registry aimed to evaluate the use of the Trevo

2017 Journal of neurointerventional surgery

136. The Association between Diffusion MRI-Defined Infarct Volume and NIHSS Score in Patients with Minor Acute Stroke Full Text available with Trip Pro

The Association between Diffusion MRI-Defined Infarct Volume and NIHSS Score in Patients with Minor Acute Stroke Prior studies have shown a correlation between the National Institutes of Health Stroke Scale (NIHSS) and stroke volume on diffusion weighted imaging (DWI); data are more limited in patients with minor stroke. We sought to determine the association between DWI lesion(s) volume and the (1) total NIHSS score and (2) NIHSS component scores in patients with minor stroke.We included all (...) patients with minor stroke (NIHSS 0-5) enrolled in the Stroke Warning Information and Faster Treatment study. We calculated lesion(s) volume (cm3 ) on the DWI sequence using Medical Image Processing, Analysis, and Visualization (MIPAV, NIH, Version 7.1.1). We used nonparametric tests to study the association between the primary outcome, DWI lesion(s) volume, and the predictors (NIHSS score and its components).We identified 894 patients with a discharge diagnosis of minor stroke; 709 underwent magnetic

2017 Journal of neuroimaging : official journal of the American Society of Neuroimaging

137. Race-Ethnic Disparities in Hospital Arrival Time after Ischemic Stroke Full Text available with Trip Pro

in the Bronx, New York. A multivariable logistic regression model was used to identify the association between race-ethnicity and hospital arrival time adjusting for age, sex, socioeconomic status (SES), NIH stroke scale (NIHSS), history of stroke, preferred language and transportation mode to the hospital.There were 338 Caucasians, 662 Hispanics, and 790 African Americans in the cohort. Compared with Caucasians, African Americans and Hispanics were younger (P<.0001 respectively), had lower SES (P<.001 (...) Race-Ethnic Disparities in Hospital Arrival Time after Ischemic Stroke Conflicting reports exist about hospital arrival time after stroke onset in Hispanics compared with African Americans and Caucasians. Our current study investigates race-ethnic disparities in hospital arrival times after stroke onset.We performed a retrospective analysis of hospital arrival times in Hispanic, African American, and Caucasian acute ischemic stroke patients (N=1790) presenting to a tertiary-care hospital

2017 Ethnicity & disease

138. Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke

. Patients must have a score on the NIH Stroke Scale 8-24, and mRS ≤ 1 Women of childbearing age should have a negative pregnancy test performed prior to inclusion Obtaining informed consent signed Exclusion Criteria: Comatose patients. brain tumour, cerebral oedema with compression of ventricles, cerebellar infarction or brainstem, or intraventricular, intracerebral or subarachnoid haemorrhage. alcohol use Active infectious disease, including HIV, hepatitis B, Hepatitis . patients with dementia. Specify (...) patients aged 40-80 years with symptoms of acute cerebral infarction of less than 24h from stroke onset. Patients with infarct size 3*3 Patients with a measurable focal neurological that must persist to the time of treatment without clinically meaningful improvement. Patients must have computerized tomography (CT) and / or magnetic resonance imaging (MRI) compatible with the clinical diagnosis of acute ischemic stroke in the territory of the middle cerebral artery before being included in the study

2017 Clinical Trials

139. Comparison of Fatigue and Recovery After Stroke Depending on the Usual Management With or Without Physical Training

hospitalisation (NIH score ≥ 6) Recurrence of the cerebrovascular event or onset of an acute cardio-vascular event between the screening and definitive inclusion Pre-stroke Rankin score ≥ 3 Pregnant patient Patient under guardianship Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov (...) contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Age > 18 years National health insurance cover 1st minor ischaemic stroke (initial NIH score ≤ 4) Satisfactory neurological recovery at discharge from hospital (modified Rankin score ≤2) Patient living close

2017 Clinical Trials

140. Enhanced Reality for Hemiparetic Arm in the Stroke Patients

information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Arm motor Fugl-Mayer scale; wrist/hand subscales ≥ 2-20 9-hole pegboard ; ≥ 25% of contra-lateral hand Exclusion Criteria: Alexander apraxia scale ≤2 NIH stroke scale question Ia-c ≥1 Nottingham sensory scale; <75% of contra-lateral hand Ashworth scale ≥3 NIH stroke scale question IX ≥2 Beck (...) termination of treatment ] 9-hole pegboard Change of Stroke impact scale [ Time Frame: 1 day before the initiation of intervention, 10 day after the initiation of intervention, and 30 days after termination of treatment ] Stroke impact scale, hand function Change of Grasp force in Newtons [ Time Frame: 1 day before the initiation of intervention, 10 day after the initiation of intervention, and 30 days after termination of treatment ] Grasp force in Newtons Change of Active range of motion of wrist joint

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>